Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model
The role of platelet-activating factor (PAF) as a mediator of increased conjunctival vascular permeability was investigated in a guinea-pig model of immediate hypersensitivity. Vascular permeability of the conjunctiva was determined by measuring the albumin content in lavage fluid (LF) after topical...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1995-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/S0962935195000317 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561838961721344 |
|---|---|
| author | F. Meijer J. L. van Delft N. J. van Haeringen |
| author_facet | F. Meijer J. L. van Delft N. J. van Haeringen |
| author_sort | F. Meijer |
| collection | DOAJ |
| description | The role of platelet-activating factor (PAF) as a mediator of increased conjunctival vascular permeability was investigated in a guinea-pig model of immediate hypersensitivity. Vascular permeability of the conjunctiva was determined by measuring the albumin content in lavage fluid (LF) after topical challenge with either PAF or ovalbumin. PAF produced a dose-dependent increase of the vascular permeability within minutes. Topical pretreatment with levocabastine, a potent histamine H1-antagonist demonstrated no effect towards the vascular permeability in response to PAF provocation. Pretreatment with eyedrops containing the specific PAF antagonist BN 52021 (1%) showed a significant inhibition of the vascular permeability (60.2%) and the clinical score (27.5%) after PAF challenge. In sensitized guinea-pigs, levocabastine showed a marked inhibition of both the vascular permeability (80.5%) and the clinical score (70%) after topical challenge with ovalbumin. BN 2021, although to a lesser extent, showed a similar effect towards the vascular permeability (26.8%) and the clinical score (28%) after antigen provocation. When BN 52021 and levocabastine were administered in combination, the vascular permeability was significantly decreased after antigen challenge in comparison with eyes pretreated with levocabastine alone. These results indicate that PAF plays a role in the acute phase of allergic conjunctivitis in the guinea-pig. |
| format | Article |
| id | doaj-art-57b1f99b779e4bad9c003b9cb601fced |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 1995-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-57b1f99b779e4bad9c003b9cb601fced2025-02-03T01:24:03ZengWileyMediators of Inflammation0962-93511466-18611995-01-014319119510.1155/S0962935195000317Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig modelF. Meijer0J. L. van Delft1N. J. van Haeringen2Biochemical Laboratory, the Netherlands Ophthalmic Research Institute, Amsterdam, The NetherlandsDepartment of Ophthalmology, Academic Hospital, Leiden, The NetherlandsBiochemical Laboratory, the Netherlands Ophthalmic Research Institute, Amsterdam, The NetherlandsThe role of platelet-activating factor (PAF) as a mediator of increased conjunctival vascular permeability was investigated in a guinea-pig model of immediate hypersensitivity. Vascular permeability of the conjunctiva was determined by measuring the albumin content in lavage fluid (LF) after topical challenge with either PAF or ovalbumin. PAF produced a dose-dependent increase of the vascular permeability within minutes. Topical pretreatment with levocabastine, a potent histamine H1-antagonist demonstrated no effect towards the vascular permeability in response to PAF provocation. Pretreatment with eyedrops containing the specific PAF antagonist BN 52021 (1%) showed a significant inhibition of the vascular permeability (60.2%) and the clinical score (27.5%) after PAF challenge. In sensitized guinea-pigs, levocabastine showed a marked inhibition of both the vascular permeability (80.5%) and the clinical score (70%) after topical challenge with ovalbumin. BN 2021, although to a lesser extent, showed a similar effect towards the vascular permeability (26.8%) and the clinical score (28%) after antigen provocation. When BN 52021 and levocabastine were administered in combination, the vascular permeability was significantly decreased after antigen challenge in comparison with eyes pretreated with levocabastine alone. These results indicate that PAF plays a role in the acute phase of allergic conjunctivitis in the guinea-pig.http://dx.doi.org/10.1155/S0962935195000317 |
| spellingShingle | F. Meijer J. L. van Delft N. J. van Haeringen Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model Mediators of Inflammation |
| title | Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model |
| title_full | Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model |
| title_fullStr | Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model |
| title_full_unstemmed | Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model |
| title_short | Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model |
| title_sort | platelet activating factor an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea pig model |
| url | http://dx.doi.org/10.1155/S0962935195000317 |
| work_keys_str_mv | AT fmeijer plateletactivatingfactoraninflammatorymediatorintheacutephaseofallergicconjunctivitisinaguineapigmodel AT jlvandelft plateletactivatingfactoraninflammatorymediatorintheacutephaseofallergicconjunctivitisinaguineapigmodel AT njvanhaeringen plateletactivatingfactoraninflammatorymediatorintheacutephaseofallergicconjunctivitisinaguineapigmodel |